hip and knee joint disease
Conditions
Interventions
A:LMWH 4000IU i.h. qd, start from the first day after operation.
B:LMWH 2000IU i.h. qd, start from the first day after operation.
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Over 18 years old; Patients undergoing total hip arthroplasty and total knee arthroplasty for end-stage joint disease ( such as osteoarthritis, rheumatoid arthritis, traumatic arthritis, hip fracture, etc.).
Exclusion criteria
Exclusion criteria: Allergy to low molecular weight heparin; preoperative hepatic or renal dysfunction; preoperative use of anticoagular medication seven days prior to surgery; history of fibrinolytic disorder or blood dyscrasia; cerebrovascular accident, myocardial infarction, New York heart association class III or IV heart failure, atrial fibrillation, history of deep vein thrombosis or pulmonary embolus, preoperative INR >1.4, aPTT >1.4 x normal, platelets <140000/mm3.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| antifactor Xa activity;ecchymosis;incidence of thrombosis (DVT PE);Postoperative hidden blood loss;Postoperative Hb drop;transfusion; | — |
Secondary
| Measure | Time frame |
|---|---|
| Coagulation indicators (PT, APTT, INR, etc.);Coagulation factors (?, ?, etc.);TEG;incision related complications;length of stay;hospitalization expenses;death; | — |
Countries
China
Contacts
Public ContactWei Huang
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed